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Background. Amyloid-b peptide species ending at positions 40 and 42 (Ab40, Ab42) are generated by the proteolytic
processing of the Alzheimer’s amyloid precursor protein (APP). Ab peptides accumulate in the brain early in the course of
Alzheimer’s disease (AD), especially Ab42. The cytoplasmic domain of APP regulates intracellular trafficking and metabolism of
APP and its carboxyl-terminal fragments (CTFa, CTFb). The role of protein phosphorylation in general, and that of the
phosphorylation state of APP at threonine-668 (Thr
668) in particular, has been investigated in detail by several laboratories
(including our own). Some investigators have recently proposed that the phosphorylation state of Thr
668 plays a pivotal role in
governing brain Ab levels, prompting the current study. Methodology. In order to evaluate whether the phosphorylation state
of Thr
668 controlled brain Ab levels, we studied the levels and subcellular distributions of holoAPP, sAPPa, sAPPb, CTFa, CTFb,
Ab40 and Ab42 in brains from ‘‘knock-in’’ mice in which a non-phosphorylatable alanyl residue had been substituted at
position 668, replacing the threonyl residue present in the wild-type protein. Conclusions. The levels and subcellular
distributions of holoAPP, sAPPa, sAPPb, CTFa, CTFb,A b40 and Ab42 in the brains of Thr
668Ala mutant mice were identical to
those observed in wild-type mice. These results indicate that, despite speculation to the contrary, the phosphorylation state of
APP at Thr
668 does not play an obvious role in governing the physiological levels of brain Ab40 or Ab42 in vivo.
Citation: Sano Y, Nakaya T, Pedrini S, Takeda S, Iijima-Ando K (2006) Physiological Mouse Brain Ab Levels Are Not Related to
the Phosphorylation State of Threonine-668 of Alzheimer’s APP. PLoS ONE 1(1): e51. doi:10.1371/journal.pone.0000051
INTRODUCTION
Alzheimer’s disease (AD) is characterized by abnormalities in post-
translational processing of two proteins, the amyloid precursor
protein (APP) and the microtubule associated protein tau [1]. A
‘‘unifying hypothesis for Alzheimer’s disease’’ has been suggested,
according to which the aberration of a single post-translational
modification, such as protein phosphorylation, might underlie
both pathologies [2–4]. Both proteins are phosphoproteins [5–7],
and cyclin-dependent protein kinase 5 (cdk5) and glycogen
synthase kinase 3b (GSK-3b) are examples of protein kinases that
can potentially phosphorylate both APP and tau [6–8].
A recent review summarizes the extensive literature linking
protein phosphorylation and APP metabolism [9]. First messen-
gers, such as neurotransmitters and hormones, impinge upon
neurons and direct APP toward the cell surface and away from the
trans Golgi network (TGN) and endocytic pathway, and hence
away from the Ab-generating b-/c-secretase pathway [ibid]. At the
cell surface, APP can be processed by a nonamyloidogenic
pathway, known as the a-secretase pathway, via a process known
as ‘‘regulated APP ectodomain shedding’’ [ibid]. With regard to
Ab generation, the regulated shedding phenomenon is noteworthy
because hyperactivation of the a-secretase pathway can lead to
relatively greater cleavage of APP by a-secretase(s), thereby
reducing or completely abolishing Ab generation [ibid]. Despite
the well-documented observation that the same protein kinase (i.e.,
protein kinase C) controls both regulated shedding by a-secretase
and the phosphorylation state of the APP cytoplasmic tail at
serine-655 (Ser
655), the phosphorylation state of APP at Ser
655 is
not involved in controlling regulated shedding of the APP
ectodomain. Primary citations for this summary are included in
[9].
The exclusion of an important role for the APP phosphorylation
state in controlling regulated APP ectodomain shedding process
raised an obvious question: ‘‘What role is played by physiological
regulation of the direct phosphorylation of APP?’’. First of all, in
brain, APP phosphorylation predominantly involves Thr
668, not
Ser
655 [6–8]. Phosphorylation at Thr
668 is detectable in mature
APP (mAPP) but not immature APP (imAPP) [7], suggesting that
the phosphorylation state of Thr
668 may regulate some aspect of
APP maturation in the early secretory pathway. In addition to
cdk5 and GSK-3b mentioned above, phosphorylation at Thr
668
can be regulated by c-jun N-terminal kinases (JNK) [10,11]. With
regard to the physiological role of APP phosphorylation, the
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668 has been reported to modulate
outgrowth of neurites in PC12 cells [12,13], the tethering to APP
of the adaptor proteins FE65 [14,15] and X11-L [16], and the
interaction of APP intracellular domain fragment (AICD) with
FE65 [14,15]. Based on these data, we have proposed a model
wherein the phosphorylation state of APP at Thr
668 may govern
the state of activation of an intracellular signaling cascade across
APP that leads to generation and translocation of AICD,
analogous to the well-characterized signaling cascade across Notch
that leads to generation and translocation of the Notch in-
tracellular domain [15].
Recently, the phosphorylation state of APP Thr
668 has been
proposed to control interaction of the APP cytoplasmic tail with
the prolyl isomerase Pin1 [2,3,17]. Interaction of Pin1 with APP
Thr
668 has been predicted to have important effects on generation
of the Ab peptide that not only accumulates in amyloid plaques
but also forms oligomers that have recently been proposed to be
the proximate mediators of neurotoxicity [18]. One report
indicated that Ab levels were decreased in the brains of Pin1-
deficient mice [17], while another report described the opposite
effect, i.e., that Pin1 deficiency increased Ab generation [2]. In
work unrelated to Pin1, Tsai et al proposed a model wherein the
Figure 1. Generation of Thr
668Ala Knock-in Mutant Mice. (A) The targeting vector (a1), a partial map of the APP gene (a2), the resultant targeted
allele (a3), and the knock-in allele after Cre recombination (a4) are illustrated. Filled boxes denote coding sequences of exons 17 and 18. Shaded parts
in exon18 correspond to the 39 non-coding region. A substitution is represented by a dot in exon 18. B, BamHI;X ,XhoI. Probes for Southern blot
analysis for screening of targeted ES clones are indicated with small bars in (a2–4). PCR primers (E1 and E2) for genotyping of mice are indicated with
small arrows in (a2 and a4). (B) Verified sequences from wild-type (T/T), and Thr
668Ala mutation homozygotes (A/A). The Thr
668 flanking genomic
region was amplified using mouse tail DNA as the template by PCR and sequenced. (C) Southern blot analysis for targeted ES cells and PCR analysis
for genotyping wild-type and knock-in mouse lines. DNA from G418-selected ES cells was digested with XhoI and analyzed by Southern blotting with
a3 9 external probe. The 13-kb and 15-kb fragments represent wild-type and targeted alleles, respectively. PCR fragments of 200-bp and 298-bp
represent wild-type and knock-in alleles, respectively. (D) Immunoblot analysis of mouse whole brain. APP was immunoprecipitated with anti-pan
APP polyclonal antibody followed by immunoblotting with anti-pan APP antibody UT-421 or anti-phospho-Thr
668-specific antibody UT-33 [7]. APP
from homozygotes has no immunoreactivity with UT-33 although the APP expression levels detected by UT-421 were indistinguishable from those of
wild-type mice. Mature APP (mAPP; N- and O-glycosylated form), immature APP (imAPP; N-glycosylated form), and phosphorylated APP (pAPP) are
indicated with arrows.
doi:10.1371/journal.pone.0000051.g001
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668 would be pivotal in
modulating the subcellular distribution of APP and generation of
Ab [4] and/or the amyloidogenic c-secretase cleavage of APP
CTFs [19]. The potential importance of APP Thr
668 phosphor-
ylation was further emphasized in a recent review [3]. Because all
these reports and reviews hinged on attribution of some biological
significance to the phosphorylation state of APP Thr
668,w e
investigated in vivo brain APP metabolism and Ab levels in mutant
mice generated by knocking into their genome an APP gene
containing a non-phosphorylatable alanyl substitution at position
668. Here we report characterization of these mice, including the
quantification and subcellular distribution of all standard APP
metabolites.
RESULTS
Generation of threonine-668 phosphorylation-site
mutant mice
We constructed targeting vectors in which an alanine (A) was
substituted for threonine (T) at position 668 in exon 18 (Fig. 1A).
Targeted C57BL/6-derived MS12 embryonic stem (ES) cells were
injected into Balb/c blastocysts. Chimeras were bred to C57BL/6
mice to generate heterozygotes. Fertilized eggs from the hetero-
zygotes were then injected with a Cre-expression plasmid vector to
delete the Pgk-neo gene cassette from the germ line via the Cre-
loxP system [20], and resulting progeny carrying a substituted
allele without the Pgk-neo gene cassette were backcrossed to
C57BL/6 mice for at least 7 generations, and then intercrossing
was performed to produce Thr
668Ala homozygous mice. Thus, the
mutant lines used in this study were coisogenic to the C57BL/6
strain. Seven generations of crossing is considered acceptable for
mice generated by a coisogenic strategy [21]. The success of the
mutagenesis was confirmed by sequencing (Fig. 1B), Southern blot,
and polymerase chain reaction (PCR) analysis (Fig. 1C). We also
confirmed the mutation by immunoblot analysis using anti-
phospho-APP Thr
668 specific antibody (Fig. 1D). There was no
anti-phospho-APP Thr
668 antibody staining in homozygotes (A/
A), while heterozygotes (T/A) had approximately half the level of
the staining that was observed in wild-type (T/T). Anti-pan APP-
specific antibody staining revealed unaltered expression levels of
APP in all genotypes (Fig. 1D).
Thr
668Ala mutation did not affect brain
development or structure
The A/A mice had no gross cytoarchitectural abnormalities as
revealed in Nissl-stained sections of the hippocampal region from
A/A mice (Fig. 2A). Other brain regions were also histologically
normal (data not shown). Furthermore, immunohistochemical
and/or immunoblotting analyses for synaptophysin (presynaptic
marker), microtubule-associated protein (MAP2; dendritic mark-
er), glial fibrillary acidic protein (GFAP; astroglial marker), X11L
(APP binding protein), and PSD95 (postsynaptic marker) revealed
noabnormalitiesinA/Amice,evenatagesof12moorolder(Fig.2B
and C). These results contrast to those from APP-null mutant mice
that showed marked decreases of synaptophysin, synapsin, and
MAP-2[22],areductionindendritelength[22],andgliosis[23].The
normalphenotypeofAPPThr
668Alamicesuggeststhatthismutation
does not cause a major loss-of-function of APP.
Analysis of APP and its metabolites in APP Thr
668Ala
knock-in mice
The brains of APP Thr
668Ala knock-in mice were analyzed for
expression of APP and for steady-state levels of its metabolites
Figure 2. Normal brain structure and expression and distribution of
proteins related to neuron and glia in Thr
668Ala mutant mice. (A)
Nissl-stained hippocampal sections show no difference between wild-
type (T/T) and Thr
668Ala mutation homozygotes (A/A). Scale bars
represent 500 mm. (B) Immunohistochemical analysis in CA1 hippo-
campal region of aged (.12 mo-old) mice. Immunostaining for GFAP
(astroglial marker), synaptophysin (presynaptic marker), and MAP-2
(neuronal dendritic marker) in hippocampal CA1 region of wild-type (T/
T) and Thr
668Ala mutant (A/A) mice are shown. S.o., stratum oriens; Py,
pyramidal cell; Rad, stratum radiatum. Scale bars represent 50 mm. (C)
Western blot analysis of APP, X11L, MAP2, synaptophysin, PSD95
(postsynaptic marker), and GFAP from the brains of 12 mo-old wild-
type (T/T) and Thr
668Ala mutant (A/A) mice.
doi:10.1371/journal.pone.0000051.g002
APP Phosphorylation and Ab
PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e51(Figs. 3 and 4; Table 1). APP Thr
668 phospho-state specific
antibodies were used to establish that the knocked-in protein was
not phosphorylated at Thr
668 (Fig. 3 and Fig. 4A). Amino-terminal
fragments of APP cleaved by a- (sAPPa) and b- (sAPPb) secretases
were quantified and compared with those of wild-type mouse brain
(Fig. 3). No differences of total amount of sAPP, sAPPa, and sAPPb
were detected between Thr
668Ala knock-in and wild-type mice.
Next, we examined protein levels of APP C-terminal fragments
(CTFs) by immunoblot analysis using anti-APP cytoplasmic tail
antibodies (Fig. 4). The phosphorylation levels of APP and CTFs
are relatively lower at the birth (P0), they increase during growth
(2-mo), and they slightly decrease during aging (12-mo). Cleavage
by a-secretase generates CTFa, which is composed of the
carboxyl-terminal 83 amino acids of APP and is also known as
C83. b-secretase can cleave APP at either the peptide bond N-
terminal to D
1 (preferred) or at the bond N-terminal to E
11; hence,
CTFb and CTFb9 fragments, C99 and C89 [24], respectively, are
generated, with the preponderant species being CTFb9/C89 [24].
Because these CTFs are phosphorylated at Thr
668 (Fig. 4B) and
generate complicated patterns [25,26], we treated samples with
lambda protein phosphatase (lPPase) in order to identify and
quantify phospho- and dephospho-CTF species precisely (Fig. 4C).
Treatment of immunoprecipitates containing these CTFs with
lPPase resulted in the appearance of three discrete bands
corresponding to dephospho-forms of C99, C89, and C83, all of
which were present at identical levels in both wild-type and
Thr
668Ala knock-in mice.
Endogenous murine Ab40 and Ab42 levels were also detected
in brain. Rodent Ab is much less prone to aggregation than is
human Ab [27], and therefore little, if any, insoluble Ab is
typically detected in the wild-type mouse brain. Nevertheless, we
extracted mouse brain Ab with 6 M guanidine chloride/TBS (the
standard protocol for dissolving insoluble Ab), and we quantified
the solubilized Ab. The levels of Ab40 and Ab42 in the brains of
wild-type and Thr
668Ala knock-in mice were indistinguishable
(Table 1).
We fractionated mouse brains using an iodixanol gradient
fractionation system identical to that described in the published
cell culture study [4] (Fig. 5). Using homogenates of wild-type
mouse brains, we observed that total mAPP as well as the
corresponding phosphorylated form were largely recovered in
fractions 5–9, where GM130 (Golgi marker protein, concentrated
in fractions 7–9) and EEA1 (early endosomal protein, concentrat-
ed in fractions 4–8) were co-distributed (upper panel). Total
Thr
668Ala mAPP in knock-in mutant mouse brains was identical
in levels and distribution except that, as expected, there was no
detectable phospho-mAPP (Fig. 5). These data do not support the
prediction [4] that the phosphorylation state of APP at Thr
668
modulates its subcellular distribution in brain in vivo.
DISCUSSION
Generation, aggregation, and deposition of Ab are key steps in the
pathogenesis of AD [1]. Ab is generated in the process of
intracellular trafficking of APP, which is type I membrane protein.
Following biosynthesis of APP, APP enters the endoplasmic
reticulum where the protein is subjected to N-glycosylation
(imAPP) and then transported to Golgi and subjected to O-
glycosylation (mAPP). In neurons, membrane vesicles containing
mAPP may be transported to nerve terminals along the axon using
a kinesin-dependent motor system or else may be transcytosed and
localized in dendrites [25]. At least some APP is exposed on the
plasma membrane. This cell-surface APP, as well as APP in the
trans Golgi network, is conveyed to the endocytic system via
clathrin-coated vesicles [28]. Thus, APP might possibly be
cleaved in one or several of compartments; i.e., the constitutive
secretory pathway, the plasma membrane, and/or the endocytic
system.
The short cytoplasmic domain of APP plays an important role
in the regulation of intracellular APP trafficking and contains
several functional motifs such as 681-GYENPTY-687, where
several regulatory proteins interact [25]. One motif in the
cytoplasmic domain of APP that has been proposed to be
functionally important is 667-VTPEER-672 which forms a type
I b-turn and amino-terminal helix capping box structure and
contributes to the stability of a carboxyl-terminal helix structure
[29,30]. The phosphorylation of Thr
668, situated within this motif,
Figure 3. APP and sAPP in wild-type and Thr
668Ala mutant mouse brain. (Left) APP and sAPP in wild-type (W) and mutant (M) mouse brain.
Homogenates of brains taken from 12-month-old mice were fractionated as described and analyzed by immunoblotting for sAPP and APP
holoprotein (22C11), APP (APP/C), phosphorylated APP (pThr
668APP), sAPPa, sAPPb and MAP2B. Protein bands observed in the insoluble fraction (ppt
panel) of sAPPb are non-specific. (Right) sAPP and APP levels are displayed. The densities of the bands from soluble APP (sAPP) were standardized to
the densities of MAP2B, and those from APP were standardized to the densities of actin. All were normalized to unity for wild-type mice (1.0). The bars
indicate means6S.D. (N.S.; n=4).
doi:10.1371/journal.pone.0000051.g003
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domain, changing its interaction with FE65 [14,15]. Because of
these structural phenomena, phosphorylation of APP at Thr
668 has
been proposed by various groups to control either the metabolism
of APP, some APP-related physiological function(s), and/or some
FE65-mediated events.
Some biological phenomena appear to correlate with APP
phosphorylation. Neurite outgrowth in PC12 cells has been
reported to correlate with the phosphorylation of APP, and
a Thr
668Glu substitution remarkably reduced neurite extension
response following treatment with NGF [12]. Membrane proteins,
including APP, act to tether FE65 to Golgi membranes, and
phosphorylation of APP releases FE65 from its membrane-protein
anchor [15,31]. The released FE65 may translocate into the
nucleus and activate gene expression [32].
However, the role for the phosphorylation state of APP at
Thr
668 in the regulation of APP metabolism in brain in vivo has not
been clarified. As mentioned above, Tsai and colleagues reported
that amino acid substitutions at Thr
668 alter the intracellular
distribution of APP in cultured cells [4]. Alternatively, a recent
model from Lu and colleagues holds that the prolyl isomerase Pin1
interacts with the phosphorylated form of APP at Thr
668 , and that
the interaction of Pin1 with APP Thr
668 has important effects on
Ab levels [2; for review, see 3]. Ab levels in Pin1-deficient brains
have been studied not only by Lu and colleagues [2], but they have
also been studied independently by Akiyama and colleagues [17].
These groups reported directly contradictory results, however,
with one group reporting that Ab levels were decreased in the brains
of Pin1-deficient mice, while the other reported that Ab levels
were increased in the brains of Pin 1-deficient mice [2,17]. Thus,
since four recent and highly visible papers [2, 4,17; rev in 3] have
emphasized the potential importance of APP Thr
668 phosphory-
lation state in controlling brain Ab levels, we investigated
brain APP metabolism and Ab levels in mutant mice generated
by knocking into the mouse genome an APP gene containing
a non-phosphorylatable alanine substitution at position 668 of
APP.
The levels and subcellular distribution of APP and all its
metabolites (sAPPa, sAPPb, CTFa, CTFb,A b40, Ab42) from the
brains of wild-type and APP Thr
668Ala mutant mice were
indistinguishable. Hence, contrary to widely publicized models
[2, 4, 17, rev in 3], the phosphorylation state of APP Thr
668 does
not play an obvious role in governing physiological levels of brain
Ab in vivo.
Of note, during the final stages of production of this manuscript,
a report appeared from Cruz et al [36] in which a revised model is
presented wherein changes in APP metabolism caused by cdk5 are
attributed to increased levels of b-APP-site cleaving enzyme
(BACE) in contrast to this group’s previous proposal [4] that the
state of phosphorylation of Thr
668 was the most important
modulator of Ab levels and subcellular distribution of APP and
its derivatives. This revised model of Tsai and colleagues, focusing
on BACE levels rather than APP phospho-Thr
668 levels [36], is
entirely consistent with what we have reported here.
It is worth noting that we cannot, of course, rule out the
possibility that pathological changes in APP Thr
668 phosphoryla-
tion state might modulate its function or metabolism. Presently, we
favor a model in which APP phosphorylation at Thr
668 may
regulate either some important physiological function of APP that
is not directly linked to the proteolytic processing pathways that
control Ab levels in brain neurons in vivo. Evidence already exists
that such functions might well include modulation of neurite
outgrowth [12,13] and/or intracellular signaling via AICD or
FE65 [14,15].
Figure 4. Aging-dependent phosphorylation of APP and APP CTFs
and quantification of CTFs in wild-type and Thr
668Ala mutant mice
brain. (A) APP phosphorylation state in brains of post-natal day 0 (P0),
young adult (2-month), and aged adult (12-month) mice. The upper
panel was probed with anti-pan-APP C-terminal antibody G369, and the
lower panel was probed with an anti-phospho-threonine-
668-specific
antibody. W, wild-type mouse; M, Thr
668Ala mutant mouse. (B) APP
carboxyl-terminal fragments (APP CTFs) in wild-type (W) and mutant (M)
mouse brain. C99 and C89 are products resulting from cleavage of APP
by BACE, while C83 results from cleavage of APP by ADAM-10/-17.
PhosphoC99 (pC99), phosphoC89 (pC89), and phosphoC83 (pC83) are
all mono-phosphorylated at Thr
668, and these peptides are numbered
here according to standard APP695 nomenclature. (C) Expression levels
of CTFa and CTFb in middle aged wild-type and Thr
668A mutant mouse
brain. Various species of CTF are schematically represented at the left
and indicated at right with bars. Samples were electrophoresed after
treatment with either buffer or l phosphatase (l PPase). The amounts
were normalized to unity for wild-type mice (1.0). The bars indicate
means6S.D. (N.S.; n=6).
doi:10.1371/journal.pone.0000051.g004
Table 1. Ab40 and Ab42 levels in brains from 24-month-old
wild-type and Thr
668Ala mutant mice.
......................................................................
Ab40 (pM) p value Ab42 (pM) p value
pM Wildtype 44610.60 963.37
Mutant 3565.76 p.0.23 1061.84 p.0.72
Results of ELISA for murine Ab [35] are expressed as means6S.E.M. (N.S.;
student’s t) and are representative of results obtained from three independent
assays, using five individual mice of each genotype in each assay.
doi:10.1371/journal.pone.0000051.t001
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Production of mutant mice
Mutant mice were generated by a standard gene knock-in method
using MS12 ES cell line derived from mice of the C57BL/6
background [33]. Briefly, a 13-kb genomic fragment from
C57BL/6 mice containing exons 17 and 18 was used for
constructing targeting vectors. The T
668A point mutation (see
Figure 1B) was introduced by PCR mutagenesis. For positive
selection, the Pgk-neo gene cassette flanked by loxP sites was
inserted at the EcoR1 site in the 39 non-coding region of APP-
exon 18. For negative selection, the diphtheria toxin A-fragment
gene cassette derived from pMC1DT-A was added to the 59 end of
the targeting vector. After transfection of MS12 ES cells derived
from the C57BL/6 mouse strain and selection with G418, targeted
clones were identified by Southern blot analyses. Chimeras,
generated by injection of the targeted MS12 ES cells into Balb/c
blastocysts, were mated with C57BL/6 mice to obtain mutant
heterozygotes. The Pgk-neo cassette flanked by loxP sites was
excised by injecting the Cre recombinase expression vector,
pCAGGS-Cre [20] into the pronucleus of heterozygous fertilized
eggs. The mouse genotypes were determined by PCR, using tail
DNA as the template and the primers (E1: 59-CACATT-
GATTTCTTTGTGCCTG-39 and E2; 59-TCTGTACAAT-
CATCCTGCAG-39), which anneal to the loxP flanking regions.
Fragments of 200 bp and 298 bp were amplified from wild-type
and knock-in mutant alleles, respectively.
Immunoblot analyses
Brains were homogenized in radioimmunoprecipitation (RIPA)
lysis buffer containing 1 mM microcystin-LR, 5 mg/ml chymosta-
tin, and 5 mg/ml leupeptin, and the clear supernatants were used
for immunoblot analysis. Aliquots of the lysates (100 mg protein)
were separated on SDS-PAGE (6% (w/v) polyacrylamide for APP,
X11L, MAP2 and PSD95, or 12.5% (w/v) polyacrylamide for
synaptophysin and GFAP, and analyzed by immunoblotting with
anti-APP cytosolic domain-specific polyclonal antibody (pAb)
G369, anti-phospho Thr
668 (pAPP)-specific pAb (Cell Signaling
Technology, MA), anti-X11L cytoplasmic domain (735-
AMFRLLTGQETPLYI-749 of human X11L)–specific mono-
clonal antibody (mAb), anti-MAP2 mAb HM-2 (Sigma, St. Louis,
MO), anti-synaptophysin mAb SVP-38 (Sigma), anti-PSD95 mAb
Clone16 (Transduction Laboratories), anti-actin MAB1501 (Che-
micon International Inc., CA) and anti-GFAP mAb GF12.24
(Progen, Germany), respectively. Immunoreactive proteins were
visualized with an enhanced chemiluminescence system (ECL;
Amersham Pharmacia Biotech, Uppsala, Sweden).
APP CTFs were detected by immunoblotting as described [34],
with modifications as described. Equal aliquots of homogenates
(100 mg) were separated by electrophoresis in a Tris-tricine gel
(16% [w/v] polyacrylamide). The separated proteins were trans-
ferred to nitrocellulose membranes, the membranes were boiled in
PBS for 5 min, and probed with anti-APP cytoplasmic domain
antibody (Sigma). Immunoreactive proteins were again visualized
with an ECL detection system (Amersham Pharmacia Biotech).
For sAPP detection, brains of mice of various ages (14,15 month-
old and 24 month-old) were homogenized in TBS buffer (50 mM
Tris-HCl, 150 mM NaCl containing 1 mM microcystin-LR, 5 mg/
mL chymostatin, and 5 mg/mL leupeptin) and centrifuged at
200,0006g for 20 min at 4uC. The pellets were subjected to two
additional cycles of resuspension in equal volumes of TBS and
centrifugation for 5 min at 200,0006g at 4uC. Samples were then
lysed in an equal volume of 26 RIPA buffer and sonicated.
Protein concentrations were quantified using a BCA protein assay
Figure 5. Subcellular distribution of APP and phospho-Thr
668 APP (PiAPP) in wild-type and Thr
668Ala mutant mouse brain. Hemi-brains from
wild-type (upper panel of six blots, labeled ‘‘Wild-type’’, far left) or mutant (lower panel of six blots; labeled ‘‘Mutant T
668A’’, far left) 5-month old mice
were used for fractionation on iodixanol density-gradients as described (4). Equal aliquots (according to volume) were analyzed by immunoblotting
with antibodies as specified: anti-early endosome antigen 1 (Transduction laboratories, EEA1, top panel), anti-cis-Golgi matrix protein (Transduction
laboratories, GM130, second panel), anti-protein disulfide isomerase (Stressgen, PDI, a marker for the endoplasmic reticulum, third panel), anti-post
synaptic density 95 (Transduction laboratories, PSD95, a synaptic membrane marker, fourth panel), anti-pan-APP (G369, fifth panel) and anti-
phospho-threonine
668 APP (Cell Signaling, bottom panel).
doi:10.1371/journal.pone.0000051.g005
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(w/v) Tris-glycine SDS-polyacrylamide gels, transferred to nitrocel-
lulose, probed with anti-sAPPb (kindly provided by T. C. Saido), or
anti-sAPPa antibody 2B3 (IBL, Takasaki, Japan) and immunoreac-
tive protein species were detected using an ECL detection system.
Immunocytochemistry
Aged mice (12 mo-old or older) were deeply anesthetized with
Avertin and transcardially perfused with physiologic saline and
then 4% (w/v) paraformaldehyde in 0.1 M Na-phosphate buffer
pH7.4 at 4uC for 20 min. The brain was excised and post-fixed
with the same fixative at 4uC overnight and cryoprotected in 30%
(w/v) sucrose/phosphate-buffered saline (PBS). The brains were
embedded into OCT compound (Sakura Fine Technical Co. Ltd.,
Tokyo, Japan) and frozen coronal sections (30 mm) were prepared.
Immunohistochemical staining was performed using the ABC
method (Vector Laboratories, Burlingame, CA). Sections were
incubated with 0.1% (v/v) Triton X-100 in PBS for 30 min at
room temperature followed by incubation with 0.3% (v/v)
hydrogen peroxide in PBS for 30 min at room temperature to
quench endogenous peroxidase activity. The sections were then
blocked with 5% (v/v) horse serum in PBS at 4uC overnight. After
an overnight incubation at 4uC with anti-GFAP (clone GF12.24),
anti-synaptophysin (DAKO Corp., CA; clone SY38), or anti-
MAP2 (Chemicon International, Inc., CA; clone MAB378) mAbs,
the sections were further incubated with horse anti-mouse IgG
conjugated to biotin (Vector Laboratories) for 1 h at room
temperature, followed by the ABC complex. The peroxidase
activity was revealed using diaminobenzidine as the chromogen.
Quantification of Ab
Endogenous mouse brain Ab40 and Ab42 were quantified with
the ELISA system developed by Mathews and colleagues as
described [35].
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